4D Molecular Therapeutics, Inc. (FDMT) Tops Q2 EPS by 1c

4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) reported Q2 EPS of ($0.77), $0.01 better than the analyst estimate of ($0.78). Revenue for the quarter came in at $240 thousand versus the consensus estimate of $848.33 thousand.

For earnings history and earnings-related data on 4D Molecular Therapeutics, Inc. (FDMT) click here.

You May Also Be Interested In

• Cantor Fitzgerald Upgrades 4D Molecular Therapeutics (FDMT) to Overweight
• Rexford Industrial closes $1.2B portfolio sale to EQT Real Estate
• Gartner places F5 in AI application security emerging market report